Kably AA, Salazar LOC, Serviere ZC, Velázquez CG, Pérez PE, Santos HR, Luna RM, Valerio E, Santana H, Gaviño GF

Idioma: Español
Referencias bibliográficas: 249
Paginas: 68-113
Archivo PDF: 631.82 Kb.

RESUMEN

Antecedentes: se estima que 15% de las parejas que viven en países industrializados son infértiles; es decir, tienen falla para concebir, en edad reproductiva, luego de 12 meses o más de coitos regulares sin anticoncepción. Durante la última década se ha incrementado la demanda de tratamientos de reproducción asistida porque se cree que ahora son más efectivos.
Objetivo: unificar el criterio terapéutico y el servicio a las pacientes y sentar el precedente para una Norma Oficial Mexicana al respecto y de ayuda para la legislación de estos procedimientos.
Método: de consenso mediante la técnica grupal de panel de expertos con la participación de 34 centros nacionales acreditados para el uso de la reproducción asistida. Se organizaron siete mesas de trabajo con la siguiente temática: 1) selección de pacientes para tratamiento de reproducción asistida; 2) esquemas de estimulación ovárica controlada para técnicas de reproducción asistida de alta complejidad; 3) preparación y técnica de captura ovular; 4) transferencia embrionaria; 5) complementación de la fase lútea; 6) indicaciones y técnicas de criopreservación y 7) consentimiento informado. Cada mesa tuvo un coordinador que redactó las conclusiones y las expuso ante el pleno, mismo que hizo una serie de observaciones hasta que se llegó a la unanimidad de criterios, que se plasman en este documento.
Resultados: la selección de pacientes para las técnicas de reproducción asistida es el primer paso de todo el proceso. Una correcta selección llevará al éxito, de la misma forma que una mala selección conducirá al fracaso. Para el caso de la ovodonación la recomendación más importante es que sólo se transfieran uno a dos embriones con el propósito de reducir las tasas de embarazo múltiple y mantener tasas elevadas de embarazo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Herrero del Collado T. La inseminación artificial ante el derecho penal. Granada: Universidad de Granada, 1969.

2. Orta García A. Inseminación artificial terapéutica, semen de donador: mitos y realidades en la selección del sexo. En: Vázquez Benítez E, editor. Medicina Reproductiva. México: Manual Moderno, 2003;305-315.

3. Angell NF, Moustafa HF, Rizk BRM, Nawar MG, et al. Intrauterine insemination. In: Rizk B, Garcia-Velasco J, Sallam H, Makrigiannakis A, editores. Infertility and assisted reproduction. Nueva York: Cambridge University Press, 2008;416-427.

4. Martinez AR, Bernardus RE, Vermeiden JP, Schoemaker J. Basic questions on intrauterine insemination: an update. Obstet Gynecol Surv 1993;48:811-828.

5. Allahbadia GN, Gandhi G, Gosrani S. Human semen banking -Where are we today? In: Allahbadia GN, editor. Intrauterine insemination. Londres: Taylor & Francis, 2005;318-340.

6. Barwin BN. Intrauterine insemination of husband’s semen. J Reprod Fertil 1974;36:101-106.

7. Hanson FM, Rock J. Artificial insemination with husband’s sperm. Fertil Steril 1951;2:162-174.

8. Nachtigall RD, Faure N, Glass RH. Artificial insemination of husband’s sperm. Fertil Steril 1979;32:141-147.

9. Orta García A. Inseminación terapéutica con semen de donador. En: Vázquez Benítez E, editor. Medicina reproductiva en México, 2a ed. México: Manual Moderno, 2003;305-308.

10. Potter RG. Artificial insemination by donors; analysis of seven series. Fertil Steril 1958;9:37-53.

11. Karande VC. Patient selection and management to optimize success in an intrauterine insemination program. In: Allahbadia GN, editor. Intrauterine insemination. Londres: Taylor & Francis, 2005;75-85.

12. Marcus SF. Intrauterine insemination. In: Brinsden PR, editor. Textbook of in vitro fertilization and assisted reproduction. Abingdon: Taylor & Francis, 2005;259-269.

13. Remohí J, Bellver A, Requena A, Pellicer A. Recuento de espermatozoides móviles. En: Remohí J, Bellver A, Requena A, Pellicer A, editores. Guía de protocolos en reproducción humana. Madrid: Momento Médico Iberoamericana, 2009;17-18.

14. Lenton EA. Stimulated intrauterine insemination: efficient, cost-effective, safe? Hum Fertil 2004;7:253-265.

15. Norwitz ER. Multiple pregnancy. Trends, past, present and future. Infert Reprod Med 1998;9:351-369.

16. Balasch J. Gonadotropin ovarian stimulation and intrauterine insemination for unexplained infertility. Reprod Biomed Online 2004;9:664-672.

17. Guzick DS, Carson SA, Coutifaris C, Overstreet JW, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. N Engl J Med 1999;340:177-183.

18. Kemmann E, Bohrer M, Shelden R, Fiasconaro G, et al. Active ovulation management increases the monthly probability of pregnancy occurrence in ovulatory women who receive intrauterine insemination. Fertil Steril 1987;48:916- 920.

19. Nyboe Andersen A, Goossens V, Bhattacharya S, Ferraretti AP, et al. Assisted reproductive technology and intrauterine inseminations in Europe, 2005: results generated from European registers by ESHRE. Hum Reprod 2009;24:1267- 1287.

20. Shenfield F, Doyle P, Valentine A, Steele SJ, et al. Effects of age, gravidity and male infertility status on cumulative conception rates following artificial insemination with cryopreserved donor semen: analysis of 2998 cycles of treatment in one centre over 10 years. Hum Reprod 1993;8:60-64.

21. Committee on Gynecologic Practice of American College of Obstetricians and Gynecologists, Practice Committee of American Society for Reproductive Medicine. Agerelated fertility decline: a committee opinion. Fertil Steril 2008;90(suppl.c5):S154-S155.

22. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, et al. Accelerated disappearance of ovarian follicles in midlife: implications for forecasting menopause. Hum Reprod 1992;7:1342-1346.

23. Reprodcutive Endocrinology and Infertility Committee, Family Physicians Advisory Committee, Maternal-Fetal Medicine Committee, Executive and Council of the Society of Obstetricians, et al. Advanced reproductive age and fertility. J Obstet Gynaecol Can 2011;33:1165-1175.

24. Johnson JA, Tough S. Delayed child-bearing. J Obstet Gynaecol Can 2012;34:80-93.

25. Pérez Peña E. Atención integral de la infertilidad, 3a ed. México: Panamericana, 2011.

26. Practice Committee of the American Society for Reproductive Medicine. Committee opinion: role of tubal surgery in the era of assisted reproductive technology. Fertil Steril 2012;97:539-545.

27. Johnson N, van Voorst S, Sowter MC, Strandell A, et al. Surgical treatment for tubal disease in women due to undergo in vitro fertilization. Cochrane Database Syst Rev 2010;20:CD002125.

28. Déchaud H, Daurès JP, Arnal F, Humeau C, et al. Does previous salpingectomy improve implantation and pregnancy rates in patients with severe tubal factor infertility who are undergoing in vitro fertilization? A pilot prospective randomized study. Fertil Steril 1998;69:1020-1025.

29. Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility. Fertil Steril 2006;86(5 suppl.1):S156-S160.

30. Coccia ME, Rizzello F, Mariani G, Bulletti C, et al. Impact of endometriosis on in vitro fertilization and embryo transfer cycles in young women: a stage-dependent interference. Acta Obstet Gynecol Scand 2011;90:1232-1238.

31. Opøien HK, Fedorcsak P, Omland AK, Abyholm T, et al. In vitro fertilization is a successful treatment in endometriosisassociated infertility. Fertil Steril 2012;97:912-918.

32. Soliman S, Daya S, Collins J, Jarrell J. A randomized trial of in vitro fertilization versus conventional treatment for infertility. Fertil Steril 1993;59:1239-1244.

33. Practice Committee of the American Society for Reproductive Medicine. Effectivenes and treatment for unexplained infertility. Fertil Steril 2006;86(5 suppl.1):S111-S114.

34. Pandian Z, Gibreel A, Bhattacharya S. In vitro fertilisation for unexplained subfertility. Cochrane Database Syst Rev 2012;18:CD003357.

35. Male Infertility Best Practice Policy Committee of the American Urological Association, Practice Committee of the American Society for Reproductive Medicine. Report on optimal evaluation of the infertile male. Fertil Steril 2006;86(5 suppl.1):S202- S209.

36. Kamel RM. Management of the infertile couple: an evidencebased protocol. Reprod Biol Endocrinol 2010;6:21.

37. Sauer MV, Kavic SM. Oocyte and embryo donation 2006: reviewing two decades of innovation and controversy. Reprod Biomed Online 2006;12:153-162.

38. Centers for Disease Control and Prevention. Assisted reproductive technology (ART). Atlanta: CDC, 2012.

39. Practice Committee of the American Society for Reproductive Medicine. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. Fertil Steril 2006;86(5 suppl.1):S127-S128.

40. Practice Committee of the American Society for Reproductive Medicine, Practice Committee of the Society for Assisted Reproductive Technology. Guidelines on number of embryos transferred. Fertil Steril 2009;92:1518-1519.

41. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006;27:170-207.

42. Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005;365:1807-1816.

43. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997;18:71-106.

44. Navot D, Rosenwaks Z, Margalioth EJ. Prognostic assessment of female fecundity. Lancet 1987;2:645-647.

45. Muasher SJ, Oehninger S, Simonetti S, Matta J, et al. The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil Steril 1988;50:298-307.

46. Padilla SL, Bayati J, Garcia JE. Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization. Fertil Steril 1990;53:288-294.

47. Seifer DB, Lambert-Messerlian G, Hogan JW, Gardiner AC, et al. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 1997;67:110-114.

48. Seifer DB, MacLaughlin DT, Christian BP, Feng B, et al. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468-471.

49. Syrop CH, Willhoite A, Van Voorhis BJ. Ovarian volume: a novel outcome predictor for assisted reproduction. Fertil Steril 1995;64:1167-1171.

50. Tomas C, Nuojua-Huttunen S, Martikainen H. Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization. Hum Reprod 1997;12:220-223.

51. Zaidi J, Barber J, Kyei-Mensah A, Bekir J, et al. Relationship of ovarian stromal blood flow at the baseline ultrasound scan to subsequent follicular response in an in vitro fertilization program. Obstet Gynecol 1996;88:779-784.

52. Howles CM, Saunders H, Alam V, Engrand P, et al. Predictive factors and a corresponding treatment algorithm for controlled ovarian stimultaion in patients treated with recombinant human follicle stimulation hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An Analysis of 1378 patients. Curr Med Res Opin 2006;22:907-918.

53. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249-261.

54. Ulug U, Bahceci M, Erden HF, Shalev E, et al. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 2002;17:310-313.

55. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin- releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 1990;71:918-922.

56. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J. Clin. Endocrinol Metab 2007;92:2931-2937.

57. D’Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2007;CD002806.

58. Oehninger S, Mayer J, Muasher S. Impact of different clinical variables on pregnancy outcome following embryo cryopreservation. Mol Cell Endocrinol 2000;169:73-77.

59. Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 2012;24:6-22.

60. Meldrum DR, Wisot A, Hamilton F, Gutlay AL, et al. Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. Fertil Steril 1989;51:455-459.

61. Muasher SJ. Use of gonadotrophin-releasing hormone agonists in controlled ovarian hyperstimulation for in vitro fertilization. Clin Ther 1992;14 (suppl. A):74-86.

62. Arslan M, Bocca S, Mirkin S, Barroso G, et al. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril 2005;84:555-569.

63. Ferraretti AP, Garcia JE, Acosta AA, Jones GS. Serum luteinizing hormone during ovulation induction with human menopausal gonadotropin for in vitro fertilization in normally menstruating women. Fertil Steril 1983;40:742-747.

64. Sterrenburg MD, Veltman-Verhulst SM, Eijkemans MJC, Hughes EG, et al. Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. Hum Reprod Update 2011;17:184-196.

65. Nargund G, Fauser BC, Macklon NS, Ombelet W, et al. The ISMAAR proposal on terminology for ovarian stimulation for IVF. Hum Reprod 2007;22:2801-2804.

66. Craft I, Gorgy A, HIll J, Menon D, et al. Will GnRH antagonists provide new hope for patients considered ‘difficult responders’ to GnRH agonist protocols? Hum Reprod 1999;14:2959-2962.

67. Karande V, Gleicher N. A rational approach to the management of low responders in in-vitro fertilization. Hum Reprod 1999;14:1744-1748.

68. Karande VC, Jones GS, Veeck LL, Muasher SL. High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients. Fertil Steril 1990;53:486- 489.

69. Saadat P, Slater CC, Jain JK, Tourgeman DE, et al. Treatment-associated serum FSH levels in very poor responders to ovarian stimulation. J Assist Reprod Genet 2003;20:395-399.

70. Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril 1994;61:880-885.

71. Brzyski RG, Muasher SJ, Droesch K, Simonetti S, et al. Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and folliclestimulating hormone for oocyte recruitment. Fertil Steril 1988;50:917-921.

72. Garcia JE, Padilla SL, Bayati J, Baramki TA. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. Fertil Steril 1990;53:302-305.

73. Winslow KL, Toner JP, Brzyski RG, Oehninger SC, et al. The gonadotropin-releasing hormone agonist stimulation test--a sensitive predictor of performance in the flare-up in vitro fertilization cycle. Fertil Steril 1991;56:711-717.

74. Faber BM, Mayer J, Cox B, Jones D, et al. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. Fertil Steril 1998;69:826-830.

75. Hugues JN, Torresani T, Herve F, Martin-Pont B, et al. Interest of growth hormone-releasing hormone administration for improvement of ovarian responsiveness to gonadotropins in poor responder women. Fertil Steril 1991;55:945-951.

76. Akman MA, Erden HF, Tosun SB, Bayazit N, et al. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum Reprod 2000;15:2145-2147.

77. Bassil S, Godin PA, Donnez J. Outcome of in-vitro fertilization through natural cycles in poor responders. Hum Reprod 1999;14:1262-1265.

78. Corfman RS, Milad MP, Bellavance TL, Ory SJ, et al. A novel ovarian stimulation protocol for use with the assisted reproductive technologies. Fertil Steril 1993;60:864-870.

79. Hwang JL, Huang LW, Hsieh BC, Tsai YL, et al. Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. Hum Reprod 2003;18:45-49.

80. Lu PY, Chen AL, Atkinson EJ, Lee SH, et al. Minimal stimulation achieves pregnancy rates comparable to human menopausal gonadotropins in the treatment of infertility. Fertil Steril 1996;65:583-587.

81. Teramoto S, Kato O. Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study. Reprod Biomed Online 2007;15:134-148.

82. Zarek SM, Muasher SJ. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited. Fertil Steril 2011;95:2449-2455.

83. Zhang J, Chang L, Sone Y, Silber S. Minimal ovarian stimulation (mini-IVF) for IVF utilizing vitrification and cryopreserved embryo transfer. Reprod Biomed Online 2010;21:485-495.

84. Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007;13:445-452.

85. Ward HJ, Balen A, Will RG. Creutzfeldt-Jakob disease and urinary gonadotrophins. Hum Reprod 2004;19:1236- 1237.

86. Balen AH, Lumholtz IB. Consensus statement on the biosafety of urinary-derived gonadotrophins with respect to Creutzfeldt-Jakob disease. Hum Reprod 2005;20:2994- 2999.

87. Remohi J. Manual práctico de esterilidad y reproducción humana, 3a ed. México: McGraw-Hill, 2008.

88. Feichtinger W. Current technology of oocyte retrieval. Curr Opin Obstet Gynecol 1992;4:697-701.

89. Trout SW, Vallerand AH, Kemmann E. Conscious sedation for in vitro fertilization. Fertil Steril 1998;69:799-808.

90. Ben-Shlomo I, Moskovich R, Golan J, Eyali V, et al. The effect of propofol anaesthesia on oocyte fertilization and early embryo quality. Hum Reprod 2000;15:2197-2199.

91. Lim JH, Yang SH, Xu Y, Yoon SH, et al. Selection of patients for natural cycle in vitro fertilization combined with in vitro maturation of immature oocytes. Fertil Steril 2009;91:1050- 1055.

92. Awonuga A, Waterstone J, Oyesanya O, Curson R, et al. A prospective randomized study comparing needles of different diameters for transvaginal ultrasound-directed follicle aspiration. Fertil Steril 1996;65:109-113.

93. Miller KA, Elkind-Hirsch K, Benson M, Bergh P, et al. A new follicle aspiration needle set is equally effective and as well tolerated as the standard needle when used in a prospective randomized trial in a large in vitro fertilization program. Fertil Steril 2004;81:191-193.

94. Tan SL, Waterstone J, Wren M, Parsons J. A prospective randomized study comparing aspiration only with aspiration and flushing for transvaginal ultrasound-directed oocyte recovery. Fertil Steril 1992;58:356-360.

95. Goldman KN, Moon KS, Yauger BJ, Payson MD, et al. Proficiency in oocyte retrieval: how many procedures are necessary for training? Fertil Steril 2011;95:2279-2282.

96. HFEA. Fifth Annual Report. London: Human Fertilization and Embryology Authority, 1996.

97. Mansour R, Aboulghar M, Serour G. Dummy embryo transfer: a technique that minimizes the problems of embryo transfer and improves the pregnancy rate in human in vitro fertilization. Fertil Steril 1990;54:678-681.

98. Neithardt AB, Segars JH, Hennessy S, James AN, et al. Embryo afterloading: a refinement in embryo transfer technique that may increase clinical pregnancy. Fertil Steril 2005;83:710-714.

99. Katariya KO, Bates GW, Robinson RD, Arthur NJ, et al. Does the timing of mock embryo transfer affect in vitro fertilization implantation and pregnancy rates? Fertil Steril 2007;88:1462-1464.

100. Groutz A, Lessing JB, Wolf Y, Yovel I, et al. Cervical dilatation during ovum pick-up in patients with cervical stenosis: effect on pregnancy outcome in an in vitro fertilization-embryo transfer program. Fertil Steril 1997;67:909-911.

101. Visser DS, Fourie FL, Kruger HF. Multiple attempts at embryo transfer: effect on pregnancy outcome in an in vitro fertilization and embryo transfer program. J Assist Reprod Genet 1993;10:37-43.

102. Glatstein IZ, Pang SC, McShane PM. Successful pregnancies with the use of laminaria tents before embryo transfer for refractory cervical stenosis. Fertil Steril 1997;67:1172-1174.

103. Prapas N, Prapas Y, Panagiotidis Y, Prapa S, et al. Cervical dilatation has a positive impact on the outcome of IVF in randomly assigned cases having two previous difficult embryo transfers. Hum Reprod 2004;19:1791-1795.

104. Serhal P, Ranieri DM, Khadum I, Wakim RA. Cervical dilatation with hygroscopic rods prior to ovarian stimulation facilitates embryo transfer. Hum Reprod 2003;18:2618-2620.

105. Mortimer D. Quality and quality management. In: Mortimer D, Mortimer ST, editors. Quality and risk management in the IVF laboratory. Cambridge: Cambrigde University Press, 2005;24-44.

106. SART, ASRM. Assisted reproductive technology in the United States. American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry, 2009.

107. Schieve LA, Peterson HB, Meikle SF, Jeng G, et al. Live-birth rates and multiple-birth risk using in vitro fertilization. JAMA 1999;282:1832-1838.

108. ASRM Practice Committee. Guidelines on number of ebryos transferred: ASRM Practice Committee Report. Birmingham: American Society for Reproductive Medicine, 1998.

109. Jain T, Missmer SA, Hornstein MD. Trends in embryotransfer practice and in outcomes of the use of assisted reproductive technology in the United States. N Engl J Med 2004;350:1639-1645.

110. Coetsier T, Dhont M. Avoiding multiple pregnancies in in-vitro fertilization: who’s afraid of single embryo transfer? Hum Reprod 1998;13:2663-2664.

111. Davis OK. Elective single-embryo transfer-has its time arrived? N Engl J Med 2004;351:2440-2442.

112. van Montfoort AP, Fiddelers AA, Janssen JM, Derhaag JG, et al. In unselected patients, elective single embryo transfer prevents all multiples, but results in significantly lower pregnancy rates compared with double embryo transfer: a randomized controlled trial. Hum Reprod 2006;21:338-343.

113. SOGC, CFAS. Guidelines for the number of embryos to transfer following in vitro fertilization No. 182, September 2006. Int J Gynaecol Obstet 2008;102:203-216.

114. De Sutter P, Van der Elst J, Coetsier T, Dhont M. Single embryo transfer and multiple pregnancy rate reduction in IVF/ICSI: a 5-year appraisal. Reprod Biomed Online 2003;6:464-469.

115. Gardner DK, Surrey E, Minjarez D, Leitz A, et al. Single blastocyst transfer: a prospective randomized trial. Fertil Steril 2004;81:551-555.

116. Koryntová D, Moosová M, Rezábek K, Pavelková I, et al. [Single embryo transfer does not compromise the pregnancy rate in patients with good IVF/ICSI prognosis]. Ceska Gynekol 2005;70:435-439.

117. Söderström-Anttila V, Vilska S. Five years of single embryo transfer with anonymous and non-anonymous oocyte donation. Reprod Biomed Online 2007;15:428-433.

118. Gerris J, De Neubourg D, Mangelschots K, Van Royen E, et al. Elective single day 3 embryo transfer halves the twinning rate without decrease in the ongoing pregnancy rate of an IVF/ICSI programme. Hum Reprod 2002;17:2626-2631.

119. Gerris JM. Single embryo transfer and IVF/ICSI outcome: a balanced appraisal. Hum Reprod Update 2005;11:105-121.

120. Thurin A, Hausken J, Hillensjö T, Jablonowska B, et al. Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization. N Engl J Med 2004;351:2392-2402.

121. Gardner DK, Lane M, Schoolcraft WB. Culture and transfer of viable blastocysts: a feasible proposition for human IVF. Hum Reprod 2000;15(suppl.6):9-23.

122. Rehman KS, Bukulmez O, Langley M, Carr BR, et al. Late stages of embryo progression are a much better predictor of clinical pregnancy than early cleavage in intracytoplasmic sperm injection and in vitro fertilization cycles with blastocyst-stage transfer. Fertil Steril 2007;87:1041-1052.

123. Diedrich K, van der Ven H, al-Hasani S, Krebs D. Establishment of pregnancy related to embryo transfer techniques after in-vitro fertilization. Hum Reprod 1989;4(suppl.8):111-114.

124. Awonuga A, Nabi A, Govindbhai J, Birch H, et al. Contamination of embryo transfer catheter and treatment outcome in in vitro fertilization. J Assist Reprod Genet 1998;15:198-201.

125. Mansour RT, Aboulghar MA. Optimizing the embryo transfer technique. Hum Reprod 2002;17:1149-1153.

126. Poindexter ANr, Thompson DJ, Gibbons WE, Findley WE, et al. Residual embryos in failed embryo transfer. Fertil Steril 1986;46:262-267.

127. Ebner T, Yaman C, Moser M, Sommergruber M, et al. The ineffective loading process of the embryo transfer catheter alters implantation and pregnancy rates. Fertil Steril 2001;76:630-632.

128. Abou-Setta AM, Mansour RT, Al-Inany HG, Aboulghar MM, et al. Among women undergoing embryo transfer, is the probability of pregnancy and live birth improved with ultrasound guidance over clinical touch alone? A systemic review and meta-analysis of prospective randomized trials. Fertil Steril 2007;88:333-341.

129. Brown JA, Buckingham K, Abou-Setta A, Buckett W. Ultrasound versus ‘clinical touch’ for catheter guidance during embryo transfer in women. Cochrane Database Syst Rev 2010;CD006107.

130. Coroleu B, Barri PN, Carreras O, Martínez F, et al. The influence of the depth of embryo replacement into the uterine cavity on implantation rates after IVF: a controlled, ultrasound-guided study. Hum Reprod 2002;17:341-346.

131. Gergely R. 3D/4D ultrasound-guided embryo transfer targeting maximal implantation potential (MIP) point increases pregnancy rate and reduces ectopic pregnancies. Hum Reprod 2010;25(suppl.1):i87.

132. Mains L, Van Voorhis BJ. Optimizing the technique of embryo transfer. Fertil Steril 2010;94:785-790.

133. Goudas VT, Hammitt DG, Damario MA, Session DR, et al. Blood on the embryo transfer catheter is associated with decreased rates of embryo implantation and clinical pregnancy with the use of in vitro fertilization-embryo transfer. Fertil Steril 1998;70:878-882.

134. Nabi A, Awonuga A, Birch H, Barlow S, et al. Multiple attempts at embryo transfer: does this affect in-vitro fertilization treatment outcome? Hum Reprod 1997;12:1188-1190.

135. NICE. NICE Clinical Guidelines 011 for Fertility. UK National Institute of Clinical Excellence, 2004.

136. Abou-Setta AM, D’Angelo A, Sallam HN, Hart RJ, et al. Post-embryo transfer interventions for in vitro fertilization and intracytoplasmic sperm injection patients. Cochrane Database Syst Rev 2009;CD006567.

137. al-Shawaf T, Dave R, Harper J, Linehan D, et al. Transfer of embryos into the uterus: how much do technical factors affect pregnancy rates? J Assist Reprod Genet 1993;10:31- 36.

138. Amarin ZO, Obeidat BR. Bed rest versus free mobilisation following embryo transfer: a prospective randomised study. BJOG 2004;111:1273-1276.

139. Botta G, Grudzinskas G. Is a prolonged bed rest following embryo transfer useful? Hum Reprod 1997;12:2489-2492.

140. Lambers MJ, Lambalk CB, Schats R, Hompes PG. Ultrasonographic evidence that bedrest after embryo transfer is useless. Gynecol Obstet Invest 2009;68:122-126.

141. Sharif K, Afnan M, Lashen H, Elgendy M, et al. Is bed rest following embryo transfer necessary? Fertil Steril 1998;69:478-481.

142. Woolcott R, Stranger J. Ultrasound tracking of the movement of embryo-associated air bubbles on standing after transfer. Hum Reprod 1998;13:2107-2109.

143. Bar-Hava I, Kernel R, Yoeli R, Ashkenazi J, et al. Immediate ambulation after embryo transfer: a prospective study. Fertil Steril 2005;83:594-597.

144. Kucuk M, Doymaz F, Urman B. Effect of energy expenditure and physical activity on the outcomes of assisted reproduction treatment. Reprod Biomed Online 2010;20:274-279.

145. Abou-Setta AM, Al-Inany HG, Mansour RT, Serour GI, et al. Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis. Hum Reprod 2005;20:3114-3121.

146. Tavaniotou A, Albano C, Smitz J, Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod 2001;16:663-667.

147. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003;88:4186-4192.

148. McAuley JW, Kroboth FJ, Kroboth PD. Oral administration of micronized progesterone: a review and more experience. Pharmacotherapy 1996;16:453-457.

149. Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril 2008;90:2116-2125.

150. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002;17:2287-2299.

151. Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010;93:847-854.

152. Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 2004;19:1176-1180.

153. Engmann L, DiLuigi A, Schmidt D, Nulsen J, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89:84-91.

154. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006;21:1894-1900.

155. Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, et al. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod 2006;21:2572-2579.

156. Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzi TB, et al. Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis. Hum Reprod Update 2011;17:734-740.

157. Babayof R, Margalioth EJ, Huleihel M, Amash A, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006;21:1260- 1265.

158. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, et al. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril 2011;95:1174-1177.

159. Boomsma CM, Keay SD, Macklon NS. Peri-implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database Syst Rev 2007;CD005996.

160. Boomsma CM, Macklon NS. Does glucocorticoid therapy in the peri-implantation period have an impact on IVF outcomes? Curr Opin Obstet Gynecol 2008;20:249-256.

161. Stern C, Chamley L, Norris H, Hale L, et al. A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies. Fertil Steril 2003;80:376-383.

162. Csapo AI, Pulkkinen MO, Ruttner B, Sauvage JP, et al. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol 1972;112:1061-1067.

163. Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973;115:759-765.

164. Filicori M, Butler JP, Crowley WFJ. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. J Clin Invest 1984;73:1638-1647.

165. Smitz J, Erard P, Camus M, Devroey P, et al. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Hum Reprod 1992;7:1225-1229.

166. Smitz J, Bourgain C, Van Waesberghe L, Camus M, et al. A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation. Hum Reprod 1993;8:40-45.

167. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropinreleasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003;88:4186-4192.

168. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002;17:2287-2299.

169. Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 2004;CD004830.

170. Posaci C, Smitz J, Camus M, Osmanagaoglu K, et al. Progesterone for the luteal support of assisted reproductive technologies: clinical options. Hum Reprod 2000;15(suppl. 1):129-148.

171. Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod 1997;12:1073-1079.

172. Penzias AS, Alper MM. Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed Online 2003;6:287-295.

173. Bouckaert Y, Robert F, Englert Y, De Backer D, et al. Acute eosinophilic pneumonia associated with intramuscular administration of progesterone as luteal phase support after IVF: case report. Hum Reprod 2004;19:1806-1810.

174. Veysman B, Vlahos I, Oshva L. Pneumonitis and eosinophilia after in vitro fertilization treatment. Ann Emerg Med 2006;47:472-475.

175. Pouly JL, Bassil S, Frydman R, Hedon B, et al. Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Hum Reprod 1996;11:2085-2089.

176. Chakravarty BN, Shirazee HH, Dam P, Goswami SK, et al. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J. Steroid Biochem. Mol Biol 2005;97:416-420.

177. Licciardi FL, Kwiatkowski A, Noyes NL, Berkeley AS, et al. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril 1999;71:614-618.

178. Propst AM, Hill JA, Ginsburg ES, Hurwitz S, et al. A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization-embryo transfer cycles. Fertil Steril 2001;76:1144-1149.

179. Smitz J, Devroey P, Faguer B, Bourgain C, et al. [A randomized prospective study comparing supplementation of the luteal phase and early pregnancy by natural progesterone administered by intramuscular or vaginal route]. Rev Fr Gynecol Obstet 1992;87:507-516.

180. Chanson A, Germond M, Lagnaux Y, Singh L, et al. Comparison of two progesterone dose regimens for luteal phase support after embryo transfer: a prospective randomized study. Human Reprod 1996;11(suppl. 1):170.

181. Check JH, Nowroozi K, Chase J, Nazari A, et al. Comparison of luteal-phase support with high- and low-dose progesterone therapy on pregnancy rates in an in vitro fertilization program. J In Vitro Fert Embryo Transf 1991;8:173-175.

182. Polyzos NP, Messini CI, Papanikolaou EG, Mauri D, et al. Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis. Fertil Steril 2010;94:2083-2087.

183. Silverberg KM, Vaughn TC, Hansard LJ, Burger NZ, et al. Vaginal (Crinone 8%) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial. Fertil Steril 2012;97:344-348.

184. Sohn SH, Penzias AS, Emmi AM, Dubey AK, et al. Administration of progesterone before oocyte retrieval negatively affects the implantation rate. Fertil Steril 1999;71:11-14.

185. Williams SC, Oehninger S, Gibbons WE, Van Cleave WC, et al. Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a randomized, prospective study. Fertil Steril 2001;76:1140-1143.

186. Baruffi R, Mauri AL, Petersen CG, Felipe V, et al. Effects of vaginal progesterone administration starting on the day of oocyte retrieval on pregnancy rates. J Assist Reprod Genet 2003;20:517-520.

187. Nyobe Andersen A, Popovic-Todorovic B, Schmidt KT, Loft A, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod 2002;17:357-361.

188. Schmidt KL, Ziebe S, Popovic B, Lindhard A, et al. Progesterone supplementation during early gestation after in vitro fertilization has no effect on the delivery rate. Fertil Steril 2001;75:337-341.

189. Stovall DW, Van Voorhis BJ, Sparks AE, Adams LM, et al. Selective early elimination of luteal support in assisted reproduction cycles using a gonadotropin-releasing hormone agonist during ovarian stimulation. Fertil Steril 1998;70:1056-1062.

190. Farhi J, Weissman A, Steinfeld Z, Shorer M, et al. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilizationembryo transfer cycles. Fertil Steril 2000;73:761-766.

191. Lukaszuk K, Liss J, Lukaszuk M, Maj B. Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilizationembryo transfer cycles. Fertil Steril 2005;83:1372-1376.

192. Var T, Tonguc EA, Doğanay M, Gulerman C, et al. A comparison of the effects of three different luteal phase support protocols on in vitro fertilization outcomes: a randomized clinical trial. Fertil Steril 2011;95:985-989.

193. Lewin A, Benshushan A, Mezker E, Yanai N, et al. The role of estrogen support during the luteal phase of in vitro fertilization-embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertil Steril 1994;62:121-125.

194. Tay PY, Lenton EA. Inhibition of progesterone secretion by oestradiol administered in the luteal phase of assisted conception cycles. Med J Malaysia 2003;58:187-195.

195. Engmann L, DiLuigi A, Schmidt D, Benadiva C, et al. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertil Steril 2008;89:554-561.

196. Serna J, Cholquevilque JL, Cela V, Martínez-Salazar J, et al. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial. Fertil Steril 2008;90:2190-2195.

197. Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril 2008;90:2116-2125.

198. Jee BC, Suh CS, Kim SH, Kim YB, et al. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. Fertil Steril 2010;93:428-436.

199. Nosarka S, Kruger T, Siebert I, Grové D. Luteal phase support in in vitro fertilization: meta-analysis of randomized trials. Gynecol Obstet Invest 2005;60:67-74.

200. Fujimoto A, Osuga Y, Fujiwara T, Yano T, et al. Human chorionic gonadotropin combined with progesterone for luteal support improves pregnancy rate in patients with low late-midluteal estradiol levels in IVF cycles. J Assist Reprod Genet 2002;19:550-554.

201. Carmichael SL, Shaw GM, Laurent C, Croughan MS, et al. Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med 2005;159:957-962.

202. DHHS. Progestational drug products for human use; requirements for labeling directed to the patient. Federal Register 1999;64:17985-17988.

203. ECASRM. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005;83:1622-1628.

204. ESHRE Task Force on Ethics and Law, Dondorp W, de Wert G, Pennings G, et al. Oocyte cryopreservation for age-related fertility loss. Hum Reprod 2012;27:1231-1237.

205. PCASRM, PCSART. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2008;90(suppl. 5):S241-S246.

206. Hourvitz A, Goldschlag DE, Davis OK, Gosden LV, et al. Intracytoplasmic sperm injection (ICSI) using cryopreserved sperm from men with malignant neoplasm yields high pregnancy rates. Fertil Steril 2008;90:557-563.

207. van Casteren NJ, Dohle GR, Romijn JC, de Muinck Keizer- Schrama SM, et al. Semen cryopreservation in pubertal boys before gonadotoxic treatment and the role of endocrinologic evaluation in predicting sperm yield. Fertil Steril 2008;90:1119-1125.

208. Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2011;96:277-285.

209. PCASRM, PCSART. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2006;86(suppl.):S142-S147.

210. Cobo A, Kuwayama M, Pérez S, Ruiz A, et al. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. Fertil Steril 2008;89:1657-1664.

211. Cobo A, Meseguer M, Remohí J, Pellicer A. Use of cryobanked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod 2010;25:2239-2246.

212. Chian RC, Huang JY, Tan SL, Lucena E, et al. Obstetric and perinatal outocme in 200 infants conceived from vitrified oocytes. Reprod Biomed Online 2008;16:608-610.

213. Chavez-Badiola A, Ruvalcaba Castellón LA, Chanona-Flores JC, García-Amador MI, et al. Live birth following in-vitro maturation of oocytes and vitrification. Further strategies in fertility preservation. Fertil Steril 2008;90(suppl.):S394-S395.

214. Tucker M, Morton P, Liebermann J. Human oocyte cryopreservation: a valid alternative to embryo cryopreservation? Eur J Obstet Gynecol Reprod Biol 2004;113(suppl. 1):S24-S27.

215. Racicot MH, Labarta E, Cobo A, Bosch E, et al. Minimal vs. conventional ovarian stimulation followed by oocyte accumulation and vitrification; a new approach for low responders before ICSI (Intracytoplasmic Sperm Injection). Fertil Steril 2011;96(suppl.):S261-S262.

216. Kuwayama M, Vajta G, Kato O, Leibo SP. Highly efficient vitrification method for cryopreservation of human oocytes. Reprod Biomed Online 2005;11:300-308.

217. Bielanski A, Bergeron H, Lau PC, Devenish J. Microbial contamination of embryos and semen during long term banking in liquid nitrogen. Cryobiology 2003;46:146-152.

218. PCASRM. Definition of «experimental procedures». Fertil Steril 2009;92:1517.

219. Ku LT, Elster N, Nakajima ST. Frozen embryos: a life-saving option. Fertil Steril 2008;90:849.

220. Juretzka MM, O’Hanlan KA, Katz SL, El-Danasouri I, et al. Embryo cryopreservation after diagnosis of stage IIB endo metrial cancer and subsequent pregnancy in a gestational carrier. Fertil Steril 2005;83:1041.

221. Loutradi KE, Kolibianakis EM, Venetis CA, Papanikolaou EG, et al. Cryopreservation of human embryos by vitrification or slow freezing: a systematic review and meta-analysis. Fertil Steril 2008;90:186-193.

222. Balaban B, Urman B, Ata B, Isiklar A, et al. A randomized controlled study of human Day 3 embryo cryopreservation by slow freezing or vitrification: vitrification is associated with higher survival, metabolism and blastocyst formation. Hum Reprod 2008;23:1976-1982.

223. Ménézo YJ, Chouteau J, Torelló J, Girard A, et al. Birth weight and sex ratio after transfer at blastocyst stage in humans. Fertil Steril 1999;72:221-224.

224. Wennerholm UB, Albertsson-Wikland K, Bergh C, Hamberger L, et al. Postnatal growth and health in children born after cryopreservation as embryos. Lancet 1998;351:1085-1090.

225. Barton SE, Missmer SA, Berry KF, Ginsburg ES. Female cancer survivors are low responders and have reduced success compared with other patients undergoing assisted reproductive technologies. Fertil Steril 2012;97:381-386.

226. Oktay K, Buyuk E, Akar M, Rosenwaks Z, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. Fertil Steril 2004;82 (suppl. 2):S1.

227. Poirot CJ, Martelli H, Genestie C, Golmard JL, et al. Feasibility of ovarian tissue cryopreservation for prepubertal females with cancer. Pediatr Blood Cancer 2007;49:74-78.

228. Andersen CY, Rosendahl M, Byskov AG, Loft A, et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum Reprod 2008;23:2266- 2272.

229. Demeestere I, Simon P, Emiliani S, Delbaere A, et al. Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin’s disease. Oncologist 2007;12:1437-1442.

230. Demeestere I, Simon P, Moffa F, Delbaere A, et al. Birth of a second healthy girl more than 3 years after cryopreserved ovarian graft. Hum Reprod 2010;25:1590-1591.

231. Dittrich R, Lotz L, Keck G, Hoffmann I, et al. Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation. Fertil Steril 2012;97:387-390.

232. Donnez J, Dolmans MM, Demylle D, Jadoul P, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405-1410.

233. Ernst E, Bergholdt S, Jørgensen JS, Andersen CY. The first woman to give birth to two children following transplantation of frozen/thawed ovarian tissue. Hum Reprod 2010;25:1280- 1281.

234. Meirow D, Levron J, Eldar-Geva T, Hardan I, et al. Pregnancy after transplantation of crypreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005;353:318-321.

235. Roux C, Amiot C, Agnani G, Aubard Y, et al. Live birth after ovarian tissue autograft in a patient with sickle cell disease treated by allogeneic bone marrow transplantation. Fertil Steril 2010;93:2413.

236. Sánchez-Serrano M, Crespo J, Mirabet V, Cobo AC, et al. Twins born after transplantation of ovarian cortical tissue and oocyte vitrification. Fertil Steril 2010;93:268.

237. Schmidt KT, Rosendahl M, Ernst E, Loft A, et al. Autotransplantation of cryopreserved ovarian tissue in 12 women with chemotherapy-induced premature ovarian failure: the Danish experience. Fertil Steril 2011;95:695-701.

238. Nugent D, Newton H, Gallivan L, Gosden RG. Protective effect of vitamin E on ischaemia-reperfusion injury in ovarian grafts. J Reprod Fertil 1998;114:341-346.

239. Silber SJ, DeRosa M, Pineda J, Lenahan K, et al. A series of monozygotic twins discordant for ovarial failure: ovary transplantation (cortical versus microvascular) and cryopreservation. Hum Reprod 2008;23:1531-1537.

240. Huang JY, Tulandi T, Holzer H, Tan SL, et al. Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation. Fertil Steril 2008;89:567- 572.

241. Brinster RL, Nagano M. Spermatogonial stem cell transplantation, cryopreservation and culture. Semin Cell Dev Biol 1998;9:401-409.

242. Avarbock MR, Brinster CJ, Brinster RL. Reconstitution of spermatogenesis from frozen spermatogonial stem cells. Nat Med 1996;2:693-696.

243. Jahnukainen K, Ehmcke J, Hergenrother SD, Schlatt S. Effect of cold storage and cryopreservation of immature nonhuman primate testicular tissue on spermatogonial stem cell potential in xenografts. Hum Reprod 2007;22:1060-1067.

244. Pérez-Peña E, Gutiérrez-Gutiérrez AM, Pascual-Rodríguez AV, González Ortega C. Preservación de la fertilidad. In: Barroso-Villa JG, editors. Biología de la reproducción en el siglo XXI. Clin Perinat y Reprod Hum 2009;III:121-142.

245. Ethics Committee of the American Society for Reproductive Medicine. Posthumous reproduction. Fertil Steril 2004;82(suppl. 1):S260-S262.

246. PCSART, PCASRM. Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion. Fertil Steril 2007;88:1495-1496.

247. Dobler López IF. Aspectos legales y éticos del consentimiento informado en la atención médica en México. Rev Mex Patol Clin 2001;48:3-6.

248. Gobierno de España. Ley 41/2002 básica reguladora de la autonomía del paciente y de derechos y obligaciones en materia de información y documentación clínica. Boletín Oficial del Estado 2002;40126-40132 (BOE-A-2002-22188).

249. Aguirre Méndez JC, Arce Círigo R. Iniciativa con proyecto de decreto que reforma la Ley General de Salud. México. Senado de la República, LVI Legislatura, 2010.